Details der Publikation - Risk of progression in chronic phase-chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation

Risk of progression in chronic phase-chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation : final analysis of the TFR-PRO study / Giovanni Paolo Maria Zambrotta, Franck E. Nicolini, Sarit Assouline, Lambert Busque, Ester Pungolino, Elisabetta Abruzzese, Maria Cristina Miggiano, Chiara Elena, Alberto Alvarez-Larran, Ana Triguero, Alessandra Iurlo, Cristina Bucelli, Marco Cerrano, Isabella Capodanno, Francesca Lunghi, Philipp le Coutre, Sara Galimberti, Giovanni Caocci, Margherita Maffioli, Fabio Stagno, Susanne Saussele, Rocco Piazza, Brian J. Druker, Carmen Fava, Veronica Guglielmana, Federica Colombo, Laura Antolini, Carlo Gambacorti-Passerini

Disease progression to accelerated/blast phase (AP/BP) in patients with chronic phase chronic myeloid leukemia (CP-CML) after treatment discontinuation (TD) has never been systematically reported in clinical trials. However, recent reports of several such cases has raised concern. To estimate the risk of AP/BP among TD-eligible patients, we conducted TFR-PRO, a cohort retro-prospective study: 870 CP-CML patients eligible for TD formed a discontinuation cohort (505 patients) and a reference one (365 patients). The primary objective was the time adjusted rate (TAR) of progression in relation to TD. Secondary endpoints included the TAR of molecular relapse, that is, loss of major molecular response (MMR). With a median follow up of 5.5 years and 5188.2 person-years available, no events occurred in the TD cohort. One event of progression was registered 55 months after the end of TD, when the patient was contributing to the reference cohort. The TAR of progression was 0.019/100 person-years (95% CI [0.003-0.138]) in the overall group; 0.0 (95% CI [0-0.163]) in the discontinuation cohort; and 0.030 (95% CI [0.004-0.215]) in the reference cohort. These differences are not statistically significant. Molecular relapses occurred in 172/505 (34.1%) patients after TD, and in 64/365 (17.5%) patients in the reference cohort, p < .0001. Similar rates were observed in TD patients in first, second or third line of treatment. CML progression in patients eligible for TD is rare and not related to TD. Fears about the risk of disease progression among patients attempting TD should be dissipated..

Medienart:	E-Artikel

Erscheinungsjahr:	November 2023 2023
Erschienen:	November 2023

Enthalten in:	Zur Gesamtaufnahme - volume:98
Enthalten in:	American journal of hematology - 98(2023), 11 vom: Nov., Seite 1762-1771

Sprache:	Englisch

Beteiligte Personen:	Zambrotta, Giovanni Paolo Maria [VerfasserIn] Nicolini, Franck E. [VerfasserIn] Assouline, Sarit [VerfasserIn] Busque, Lambert [VerfasserIn] Pungolino, Ester [VerfasserIn] Abruzzese, Elisabetta [VerfasserIn] Miggiano, Maria Cristina [VerfasserIn] Elena, Chiara [VerfasserIn] Alvarez-Larran, Alberto [VerfasserIn] Triguero, Ana [VerfasserIn] Iurlo, Alessandra [VerfasserIn] Bucelli, Cristina [VerfasserIn] Cerrano, Marco [VerfasserIn] Capodanno, Isabella [VerfasserIn] Lunghi, Francesca [VerfasserIn] le Coutre, Philipp [VerfasserIn] Galimberti, Sara [VerfasserIn] Caocci, Giovanni [VerfasserIn] Maffioli, Margherita [VerfasserIn] Stagno, Fabio [VerfasserIn] Saußele, Susanne, 1968- [VerfasserIn] Piazza, Rocco [VerfasserIn] Druker, Brian J. [VerfasserIn] Fava, Carmen [VerfasserIn] Guglielmana, Veronica [VerfasserIn] Colombo, Federica [VerfasserIn] Antolini, Laura [VerfasserIn] Gambacorti-Passerini, Carlo [VerfasserIn]

Links:	Volltext [kostenfrei] Volltext [kostenfrei]

Anmerkungen:	Online veröffentlicht: 30. August 2023 Gesehen am 30.01.2024

Umfang:	Illustrationen 10

doi:	10.1002/ajh.27073

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	1879512424

Internformat


LEADER	01000caa a2200265 4500
001	1879512424
003	DE-627
005	20240307025256.0
007	cr uuu---uuuuu
008	240130s2023 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1002/ajh.27073 \|2 doi
035			\|a (DE-627)1879512424
035			\|a (DE-599)KXP1879512424
035			\|a (OCoLC)1425207576
040			\|a DE-627 \|b ger \|c DE-627 \|e rda
041			\|a eng
100	1		\|a Zambrotta, Giovanni Paolo Maria \|e verfasserin \|0 (DE-588)1317621581 \|0 (DE-627)1879513951 \|4 aut
245	1	0	\|a Risk of progression in chronic phase-chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation \|b final analysis of the TFR-PRO study \|c Giovanni Paolo Maria Zambrotta, Franck E. Nicolini, Sarit Assouline, Lambert Busque, Ester Pungolino, Elisabetta Abruzzese, Maria Cristina Miggiano, Chiara Elena, Alberto Alvarez-Larran, Ana Triguero, Alessandra Iurlo, Cristina Bucelli, Marco Cerrano, Isabella Capodanno, Francesca Lunghi, Philipp le Coutre, Sara Galimberti, Giovanni Caocci, Margherita Maffioli, Fabio Stagno, Susanne Saussele, Rocco Piazza, Brian J. Druker, Carmen Fava, Veronica Guglielmana, Federica Colombo, Laura Antolini, Carlo Gambacorti-Passerini
264		1	\|c November 2023
300			\|b Illustrationen
300			\|a 10
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a Online veröffentlicht: 30. August 2023
500			\|a Gesehen am 30.01.2024
520			\|a Disease progression to accelerated/blast phase (AP/BP) in patients with chronic phase chronic myeloid leukemia (CP-CML) after treatment discontinuation (TD) has never been systematically reported in clinical trials. However, recent reports of several such cases has raised concern. To estimate the risk of AP/BP among TD-eligible patients, we conducted TFR-PRO, a cohort retro-prospective study: 870 CP-CML patients eligible for TD formed a discontinuation cohort (505 patients) and a reference one (365 patients). The primary objective was the time adjusted rate (TAR) of progression in relation to TD. Secondary endpoints included the TAR of molecular relapse, that is, loss of major molecular response (MMR). With a median follow up of 5.5 years and 5188.2 person-years available, no events occurred in the TD cohort. One event of progression was registered 55 months after the end of TD, when the patient was contributing to the reference cohort. The TAR of progression was 0.019/100 person-years (95% CI [0.003-0.138]) in the overall group; 0.0 (95% CI [0-0.163]) in the discontinuation cohort; and 0.030 (95% CI [0.004-0.215]) in the reference cohort. These differences are not statistically significant. Molecular relapses occurred in 172/505 (34.1%) patients after TD, and in 64/365 (17.5%) patients in the reference cohort, p < .0001. Similar rates were observed in TD patients in first, second or third line of treatment. CML progression in patients eligible for TD is rare and not related to TD. Fears about the risk of disease progression among patients attempting TD should be dissipated.
700	1		\|a Nicolini, Franck E. \|e verfasserin \|4 aut
700	1		\|a Assouline, Sarit \|e verfasserin \|4 aut
700	1		\|a Busque, Lambert \|e verfasserin \|4 aut
700	1		\|a Pungolino, Ester \|e verfasserin \|4 aut
700	1		\|a Abruzzese, Elisabetta \|e verfasserin \|4 aut
700	1		\|a Miggiano, Maria Cristina \|e verfasserin \|4 aut
700	1		\|a Elena, Chiara \|e verfasserin \|4 aut
700	1		\|a Alvarez-Larran, Alberto \|e verfasserin \|4 aut
700	1		\|a Triguero, Ana \|e verfasserin \|4 aut
700	1		\|a Iurlo, Alessandra \|e verfasserin \|4 aut
700	1		\|a Bucelli, Cristina \|e verfasserin \|4 aut
700	1		\|a Cerrano, Marco \|e verfasserin \|4 aut
700	1		\|a Capodanno, Isabella \|e verfasserin \|4 aut
700	1		\|a Lunghi, Francesca \|e verfasserin \|4 aut
700	1		\|a le Coutre, Philipp \|e verfasserin \|4 aut
700	1		\|a Galimberti, Sara \|e verfasserin \|4 aut
700	1		\|a Caocci, Giovanni \|e verfasserin \|4 aut
700	1		\|a Maffioli, Margherita \|e verfasserin \|4 aut
700	1		\|a Stagno, Fabio \|e verfasserin \|4 aut
700	1		\|a Saußele, Susanne \|d 1968- \|e verfasserin \|0 (DE-588)115839860 \|0 (DE-627)69162786X \|0 (DE-576)29010694X \|4 aut
700	1		\|a Piazza, Rocco \|e verfasserin \|4 aut
700	1		\|a Druker, Brian J. \|e verfasserin \|4 aut
700	1		\|a Fava, Carmen \|e verfasserin \|4 aut
700	1		\|a Guglielmana, Veronica \|e verfasserin \|4 aut
700	1		\|a Colombo, Federica \|e verfasserin \|4 aut
700	1		\|a Antolini, Laura \|e verfasserin \|4 aut
700	1		\|a Gambacorti-Passerini, Carlo \|e verfasserin \|4 aut
773	0	8	\|i Enthalten in \|t American journal of hematology \|d New York, NY : Wiley-Liss, 1976 \|g 98(2023), 11 vom: Nov., Seite 1762-1771 \|h Online-Ressource \|w (DE-627)302923349 \|w (DE-600)1492749-4 \|w (DE-576)094060002 \|x 1096-8652 \|7 nnns
773	1	8	\|g volume:98 \|g year:2023 \|g number:11 \|g month:11 \|g pages:1762-1771 \|g extent:10
856	4	0	\|u https://doi.org/10.1002/ajh.27073 \|x Verlag \|x Resolving-System \|z kostenfrei \|3 Volltext
856	4	0	\|u https://onlinelibrary.wiley.com/doi/abs/10.1002/ajh.27073 \|x Verlag \|z kostenfrei \|3 Volltext
912			\|a GBV_USEFLAG_U
912			\|a GBV_ILN_2013
912			\|a ISIL_DE-16-250
912			\|a SYSFLAG_1
912			\|a GBV_KXP
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_32
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_90
912			\|a GBV_ILN_95
912			\|a GBV_ILN_100
912			\|a GBV_ILN_101
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_120
912			\|a GBV_ILN_138
912			\|a GBV_ILN_150
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_171
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_224
912			\|a GBV_ILN_230
912			\|a GBV_ILN_266
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_370
912			\|a GBV_ILN_602
912			\|a GBV_ILN_636
912			\|a GBV_ILN_647
912			\|a GBV_ILN_702
912			\|a GBV_ILN_2001
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2004
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2006
912			\|a GBV_ILN_2007
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2010
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2015
912			\|a GBV_ILN_2020
912			\|a GBV_ILN_2021
912			\|a GBV_ILN_2025
912			\|a GBV_ILN_2026
912			\|a GBV_ILN_2027
912			\|a GBV_ILN_2031
912			\|a GBV_ILN_2034
912			\|a GBV_ILN_2037
912			\|a GBV_ILN_2038
912			\|a GBV_ILN_2039
912			\|a GBV_ILN_2044
912			\|a GBV_ILN_2048
912			\|a GBV_ILN_2049
912			\|a GBV_ILN_2050
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2056
912			\|a GBV_ILN_2057
912			\|a GBV_ILN_2061
912			\|a GBV_ILN_2064
912			\|a GBV_ILN_2068
912			\|a GBV_ILN_2088
912			\|a GBV_ILN_2093
912			\|a GBV_ILN_2106
912			\|a GBV_ILN_2108
912			\|a GBV_ILN_2110
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_2112
912			\|a GBV_ILN_2113
912			\|a GBV_ILN_2118
912			\|a GBV_ILN_2119
912			\|a GBV_ILN_2122
912			\|a GBV_ILN_2129
912			\|a GBV_ILN_2143
912			\|a GBV_ILN_2144
912			\|a GBV_ILN_2147
912			\|a GBV_ILN_2148
912			\|a GBV_ILN_2152
912			\|a GBV_ILN_2153
912			\|a GBV_ILN_2190
912			\|a GBV_ILN_2232
912			\|a GBV_ILN_2336
912			\|a GBV_ILN_2446
912			\|a GBV_ILN_2470
912			\|a GBV_ILN_2472
912			\|a GBV_ILN_2507
912			\|a GBV_ILN_2522
912			\|a GBV_ILN_2548
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4035
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4046
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4242
912			\|a GBV_ILN_4246
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4251
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4326
912			\|a GBV_ILN_4333
912			\|a GBV_ILN_4334
912			\|a GBV_ILN_4335
912			\|a GBV_ILN_4336
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4393
912			\|a GBV_ILN_4700
912			\|a GBV_ILN_2403
912			\|a GBV_ILN_2403
912			\|a ISIL_DE-LFER
951			\|a AR
952			\|d 98 \|j 2023 \|e 11 \|c 11 \|h 1762-1771 \|g 10
980			\|2 2013 \|1 01 \|x DE-16-250 \|b 447231245X \|c 00 \|f --%%-- \|d --%%-- \|e --%%-- \|j --%%-- \|y l01 \|z 30-01-24
980			\|2 2403 \|1 01 \|x DE-LFER \|b 4478595372 \|c 00 \|f --%%-- \|d --%%-- \|e n \|j --%%-- \|y l01 \|z 07-02-24
981			\|2 2403 \|1 01 \|x DE-LFER \|r https://doi.org/10.1002/ajh.27073
981			\|2 2403 \|1 01 \|x DE-LFER \|r https://onlinelibrary.wiley.com/doi/abs/10.1002/ajh.27073
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 00 \|s s \|a hd2023
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 01 \|s s \|0 (DE-627)1410508463 \|a wissenschaftlicher Artikel (Zeitschrift)
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 02 \|s s \|a per_28
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 03 \|s s \|a s_10
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 04 \|s p \|0 (DE-627)145195381X \|a Saußele, Susanne
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 04 \|s k \|0 (DE-627)1416468528 \|a III. Medizinische Klinik
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 04 \|s s \|0 (DE-627)1410501914 \|a Verfasser
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 04 \|s s \|a pos_21

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände